Copyright
©The Author(s) 2018.
World J Gastroenterol. Jul 7, 2018; 24(25): 2673-2685
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2673
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2673
Therapeutic agent | Active compound | Mode of action | Ref. |
Aminosalicylates (ASA) | 5-ASA | Decreases MPO activity, inhibits β-catenin activation | [23] |
Inhibits the generation and activity of IL-1β, IL-4, IL-5, IL-8, granulocyte-macrophage colony stimulating factor, and TNF-α | |||
Corticosteroids | Corticosteroids | [24] | |
Immunosuppressants | Azathioprine | Clinical remission | [25] |
6-mercaptopurine | Mucosal healing | ||
Cyclosporine A | |||
Tacrolimus | |||
Methotrexaten | |||
Antibiotics | Metronidazole | Decrease disease activity index | [26] |
Ciprofloxacin | Maintain remission | ||
Biological therapy | Infliximab | Neutralizes TNF-α | [27] |
Adalimumab | Reduces inflammation | ||
Certolizumab |
Base material | Main compounds/agents | Mode of action | Ref. |
Probiotics | |||
Lactic acid bacteria | Lactobacillus suntoryeus | Inhibited the activation of TLR-4-linked NF-κB activation | [32] |
Lactococcus lactis subsp. lactis S-SU2 | Prevented the colonic shortening, lowering of liver and thymus weights, and spleen enlargement | [33] | |
Lactobacillus paracasei LS2 (from kimchi) | Increased IL-10 | [34] | |
Reduced TNF-α, IFN-γ, IL-1β and MPO activity | |||
Lactococcus lactis NZ9000 (NZ-HO) | Reduced CD11b+ F4/80+ and CD11b+ Gr-1+ | [35] | |
Lactobacillus plantarum AN1 | Increased IL-10; reduced IL-1α and IL-6 | [36] | |
Lactobacillus sakei K040706 | Ameliorated the atrophy of colon length, mucosal damage, and spleen enlargement | [38] | |
Bifidobacteria | Bifidobacterium bifidum 231 | Reduced the expression of iNOS, TNF-α, IL-1β, and IL-6 | [41] |
Bifidobacterium longum CCM7952 | Suppressed NF-κB, STAT3, and TLR4 expression | [31] | |
Increased IL-10; Decreased IL-1β | |||
Engaged TLR2; Contained NOD2 | |||
Improved epithelial barrier | |||
Dietary fibers and prebiotics | |||
Konjac glucomannan | Konjac glucomannan hydrolysate | Reduced bowel movement, diarrhea, blood in feces, abdominal pain, and flatulence | [44] |
Glucan | β-(1,3–1,6)-d-glucan | Improved fecal output | [45] |
Oat β-glucan | Reduced visceral pain | [46] | |
Lowered MPO, NO, and MDA | |||
Inhibited the expressions of TNF-α, IL-1β, IL-6 and iNOS | |||
Glucan from mushroom (Pleurotus pulmonarius) | Reduced histological damage | [47] | |
Bacterial β-(1,3)-glucan | Reduced the expression of IL-1β | [48] | |
Reversed Treg reduction | |||
Nanofiber | Cellulose nanofiber from seaweed | Decreased NK cell defects and IgA production | [49] |
Prebiotics | Cellulose nanofiber from pear | Improved intestinal tissue injury | [50] |
Suppressed the activation of NF-κB | |||
Fructooligosaccharides | Suppressed colon atrophy | [51] | |
Suppressed the activation of NF-κB | |||
Goat milk oligosaccharide | Decreased IFN-γ, IL-17, and TNF-α levels | [52] | |
Inulin | Increased LAB population | [53] | |
Decreased inflammation | |||
Improved mucosal damage | |||
Decreased TNFα, COX-2, IL-2, and IL-6 | |||
Vitamins | 1alpha,25-dihydroxyvitamin D3 | Suppressed TNF-α | [57] |
Enhanced IL-10 production | |||
1,25-dihydroxyvitamin D3 | Reduced IFN-γ | [58] | |
Vitamin D3 | Increased CD+ T cells and IL-6 | [59] | |
Protected mitochondria | |||
Vitamin A | Inhibited nuclear respiratory factor (NFR)-1 and mitochondrial transcription factor A (TFAM) | [60] |
Base material | Main compound/agent | Mode of action | Ref. |
Extracts | |||
Mushroom | Coriolus versicolor extract | Reduced TNF-α, IL-1β and IL-6 | [68] |
Reduced STAT1 and STAT6 | |||
Cordiceps militaris extract | Decreased epithelial damage | [70] | |
Suppressed iNOS and TNF-α mRNA expression | |||
Inonotus obliquus extract | Suppressed TNF-α, COX-2, and IFN-γ | [73] | |
Ganoderma lucidum extract | Inhibited MAPK phosphorylation and NF-κB activation | [74] | |
Decreased histological score | |||
Fruit extracts | |||
Prunus mume | Prunus mume extract | Suppressed mucosal damage, TNF-α, and iNOS expressions | [75] |
Pomegranate | Pomegranate extract (ellagitannins and ellagic acid) | Decreased the expression of TNF-α, COX-2, IL-4, and STAT6 | [77] |
Prevented the translocation of NF-κB | [78] | ||
Cranberry | Cranberry fruit/extract | Modulated NF-κB and IL-1β signaling | [79] |
Blueberry extract | Attenuated colon shortening | ||
Suppressed pro-inflammatory cytokines | [80] | ||
Averrhoa bilimbi | Averrhoa bilimbi L. extract | Prevented oxidation | |
Inhibited pro-inflammatory mediators | [81] | ||
Aronia melanocarpa | Arronia melanocarpa juice | Reduced NF-κB translocation | |
Ginger | Ginger extract (zingerone) | Decreased mucosal injury | [82] |
Marine food | Decrease the level of pro-inflammatory cytokines | [83] | |
Haliotis discus hannai Ino extract | Improved colonic damage | [84] | |
Decreased TBARS concentration | |||
Suppressed NF-κB and IL-1β | |||
Green algae extract | Suppressed colonic tissue damage | ||
Downregulated IFN-γ and IL-4 | |||
Ameliorated colonic tissue damage | |||
Decreased pro-inflammatory cytokines | |||
Phytochemicals | Apple polyphenols | Reduced COX-2 and TNF-α | [85] |
Recovered transglutaminase protein | |||
Resveratrol | Suppressed NF-κB and TNF-α | [86] | |
Reduced clinical score | |||
Cardamonin | Reduced histopathological damage | [18] | |
Reduced iNOS, NF-κB, TNF-α, COX-2, and caspase-3 | |||
Suppressed IL-1β and TNF-α | |||
Ginsenoside Rg1 | Reduced colonic damage and DAI | [90] | |
Improved colon shortening and DAI | |||
Sulforaphane | Suppressed STAT3 expression | [91] | |
Curcumin | Reduced TNF-α, IL-1β, and MPO | [92] | |
Attenuated morphological damage |
- Citation: Mijan MA, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. World J Gastroenterol 2018; 24(25): 2673-2685
- URL: https://www.wjgnet.com/1007-9327/full/v24/i25/2673.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i25.2673